uu.seUppsala universitets publikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
The potential of the inodilator levosimendan in maintaining quality of life in advanced heart failure
Helsinki Univ Hosp, Meilahti Tower Hosp, Heart & Lung Ctr, PL 340, Helsinki 00029, Finland..
Hosp Sao Francisco Xavier, Ctr Hosp Lisboa Ocidental, Dept Internal Med, Heart Failure Unit, P-1449005 Lisbon, Portugal..
Hosp Santa Maria, Ctr Hosp Lisboa Norte, Dept Cardiol, Av Prof Egas Moniz, P-1649035 Lisbon, Portugal..
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska fakulteten, Institutionen för medicinska vetenskaper, Kardiologi.
2017 (engelsk)Inngår i: European Heart Journal, Supplement, ISSN 1520-765X, E-ISSN 1554-2815, Vol. 19, nr C, s. C15-C21Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Maintaining adequate quality of life (QoL) is an important therapeutic objective for patients with advanced heart failure and, for some patients, may take precedence over prolonging life. Achieving good QoL in this context may involve aspects of patient care that lie outside the familiar limits of heart failure treatment. The inodilator levosimendan may be advantageous in this setting, not least because of its sustained duration of action, ascribed to a long-acting metabolite designated OR-1896. The possibility of using this drug in an outpatient setting is a notable practical advantage that avoids the need for patients to attend a clinic appointment. Intermittent therapy can be integrated into a wider system of outreach and patient monitoring. Practical considerations in the use of levosimendan as part of a palliative or end-of-life regimen focused on preserving QoL include the importance of starting therapy at low doses and avoiding bolus administration unless immediate effects are required and patients have adequate baseline arterial blood pressure.

sted, utgiver, år, opplag, sider
OXFORD UNIV PRESS , 2017. Vol. 19, nr C, s. C15-C21
Emneord [en]
Levosimendan, Inodilatation, Quality of life, End-of-life, Advanced heart failure, Repetitive dosing
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-320267DOI: 10.1093/eurheartj/sux003ISI: 000397238000004OAI: oai:DiVA.org:uu-320267DiVA, id: diva2:1089130
Tilgjengelig fra: 2017-04-18 Laget: 2017-04-18 Sist oppdatert: 2017-04-18bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekst

Personposter BETA

Wikström, Gerhard

Søk i DiVA

Av forfatter/redaktør
Wikström, Gerhard
Av organisasjonen
I samme tidsskrift
European Heart Journal, Supplement

Søk utenfor DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric

doi
urn-nbn
Totalt: 369 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf